Cargando…

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia

Vascular factors increase the risks of developing Alzheimer's disease (AD) and they contribute to AD pathology. Since amyloid beta (Aβ) deposits can be observed in both diseases, there is an overlap which impedes a clear discrimination and difficult clinical diagnosis. In the present study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llorens, Franc, Schmitz, Matthias, Knipper, Tobias, Schmidt, Christian, Lange, Peter, Fischer, Andre, Hermann, Peter, Zerr, Inga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601075/ https://www.ncbi.nlm.nih.gov/pubmed/28955218 http://dx.doi.org/10.3389/fnagi.2017.00289

Ejemplares similares

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease
por: Podlesniy, Petar, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies
por: Canaslan, Sezgi, et al.
Publicado: (2021)

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients
por: Schmitz, Matthias, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
por: Kaerst, Lisa, et al.
Publicado: (2013)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
por: Ermann, Natalia, et al.
Publicado: (2018)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Progress in CSF biomarker discovery in sCJD
por: Llorens, Franc, et al.
Publicado: (2016)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer’s Disease
por: Hermann, Peter, et al.
Publicado: (2022)

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients
por: Zerr, Inga, et al.
Publicado: (2019)

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
por: Schmitz, Matthias, et al.
Publicado: (2022)

Investigating the Association of ApoE Genotypes with Blood-Brain Barrier Dysfunction Measured by Cerebrospinal Fluid-Serum Albumin Ratio in a Cohort of Patients with Different Types of Dementia
por: Karch, André, et al.
Publicado: (2013)

Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2019)

Rapidly progressive dementias — aetiologies, diagnosis and management
por: Hermann, Peter, et al.
Publicado: (2022)

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers
por: Hermann, Peter, et al.
Publicado: (2022)

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease
por: Zerr, Inga, et al.
Publicado: (2021)

MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives
por: Kanata, Eirini, et al.
Publicado: (2018)

Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease
por: Sweeney, Melanie D, et al.
Publicado: (2015)

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
por: Alexopoulos, Panagiotis, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Different Inflammatory Signatures in Alzheimer’s Disease and Frontotemporal Dementia Cerebrospinal Fluid
por: Boström, Gustaf, et al.
Publicado: (2021)

Case Report: Alzheimer's Dementia Associated With Cerebrospinal Fluid Neurochondrin Autoantibodies
por: Hansen, Niels, et al.
Publicado: (2022)

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
por: Andrés-Benito, Pol, et al.
Publicado: (2020)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Cerebrospinal Fluid Protein Profiles in Alzheimer’s Dementia Patients: A Bioinformatic Approach
por: Misra, Anamika, et al.
Publicado: (2023)

Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer’s disease and multiple sclerosis
por: Stoeck, Katharina, et al.
Publicado: (2014)

Cerebrospinal fluid catecholamines in delirium and dementia
por: Henjum, Kristi, et al.
Publicado: (2021)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
por: Llorens, Franc, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer’s disease
por: Casoli, Tiziana, et al.
Publicado: (2019)

Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimer’s Disease and Dementia with Lewy Bodies
por: Longobardi, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sokr9bv3nq70aofvjsb3d3dolo